DWA
STML

Dorsey Wright & Associates’s Stemline Therapeutics, Inc. STML Stock Holding History

Dorsey Wright & Associates’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-755
Closed -$13K – 371
2018
Q3 		$13K Buy
+755
New +$12.1K ﹤0.01% 256

Other funds holding STML

PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Dorsey Wright & Associates's STML Position: Q4 2018 in Review

Dorsey Wright & Associates sold out of Stemline Therapeutics, Inc. (STML) in Q4 2018, closing a stake of 755 shares — an estimated $13K sold.

Dorsey Wright & Associates first reported a position in STML in Q3 2018 and held it in 1 quarter. The position peaked at $13K in Q3 2018. 92 funds tracked by Wall St. Rank hold STML as of Q4 2018.

  • Dorsey Wright & Associates reported no remaining Stemline Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • Dorsey Wright & Associates sold 755 Stemline Therapeutics, Inc. shares in Q4 2018, an estimated $13K.
  • Dorsey Wright & Associates first reported a position in Stemline Therapeutics, Inc. in Q3 2018 and held it in 1 quarter.
  • Dorsey Wright & Associates's Stemline Therapeutics, Inc. position peaked at $13K in Q3 2018.
  • 92 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2018.

Based on Dorsey Wright & Associates's 13F filing for Q4 2018, filed 7 Jan 2019.